Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Bought by US Bancorp DE

US Bancorp DE grew its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 9.7% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 16,268 shares of the specialty pharmaceutical company’s stock after buying an additional 1,444 shares during the quarter. US Bancorp DE’s holdings in Jazz Pharmaceuticals were worth $2,320,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Machina Capital S.A.S. purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $29,000. Signaturefd LLC lifted its position in shares of Jazz Pharmaceuticals by 56.3% in the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 72 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Jazz Pharmaceuticals by 120.0% in the second quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 120 shares in the last quarter. Clear Perspective Advisors LLC purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $81,000. Finally, Commonwealth Bank of Australia lifted its position in shares of Jazz Pharmaceuticals by 20.5% in the second quarter. Commonwealth Bank of Australia now owns 775 shares of the specialty pharmaceutical company’s stock valued at $110,000 after acquiring an additional 132 shares in the last quarter. Institutional investors and hedge funds own 87.62% of the company’s stock.

In other Jazz Pharmaceuticals news, Director Catherine A. Sohn sold 726 shares of Jazz Pharmaceuticals stock in a transaction on Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the sale, the director now owns 9,574 shares in the company, valued at $1,298,713.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of Jazz Pharmaceuticals stock in a transaction on Monday, August 12th. The shares were sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals stock traded down $0.04 during trading on Friday, reaching $129.21. 474,759 shares of the company were exchanged, compared to its average volume of 508,497. Jazz Pharmaceuticals PLC has a 52-week low of $113.52 and a 52-week high of $169.82. The company has a market capitalization of $7.39 billion, a P/E ratio of 10.56, a PEG ratio of 1.61 and a beta of 1.10. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. The stock’s 50 day simple moving average is $132.05 and its two-hundred day simple moving average is $134.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, topping the Zacks’ consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The firm had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. During the same quarter last year, the business posted $3.49 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. As a group, equities analysts forecast that Jazz Pharmaceuticals PLC will post 13.44 earnings per share for the current year.

Several research firms have recently weighed in on JAZZ. Mizuho set a $148.00 target price on Jazz Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, July 3rd. Barclays raised their target price on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. TheStreet upgraded Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. Piper Jaffray Companies downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $205.00 to $142.00 in a research report on Wednesday, August 21st. Finally, Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the company’s stock. Jazz Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $168.43.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Net Margin

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.